Silexion Therapeutics Corp (SLXN)

$1.95 +0.07 (3.72%)
Market Cap 788,000.00
Revenue (ttm) 0.00
Net Income (ttm) -11.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,300
Avg Vol 148,428
Day's Range N/A - N/A
Shares Out 419,000.00
Stochastic %K 40%
Beta -0.26
Analysts Sell
Price Target $60.00

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel
gofefego
gofefego Aug. 3 at 8:34 PM
$SLXN https://chatgpt.com/s/t_6a70fb4479808191b26f557bdfaf3505
0 · Reply
gofefego
gofefego Aug. 3 at 8:20 PM
$SLXN has 1,06m outstanding shares with 806k float (Webull). Last week it announced it began phase 2/3 trial in pancreatic cancer. Today it announced it regained Nasdaq compliance. What else does it need to run like $DFNS $CYCU?
0 · Reply
Amuldee
Amuldee Aug. 3 at 4:03 PM
$SLXN come om
0 · Reply
focafoca99
focafoca99 Aug. 3 at 2:24 PM
$SLXN restores audit committee compliance with Nasdaq rule after board appointment.
0 · Reply
Amuldee
Amuldee Jul. 31 at 8:16 PM
$SLXN anyone here
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 31 at 6:07 PM
$SLXN overnight swing idea 1.51 and 1.60 so far $2+ now
1 · Reply
SFG1
SFG1 Jul. 30 at 7:40 PM
$SLXN Looks like somebody is "painting tape"
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 7:19 PM
$SLXN posted at bottomed 1..60 then again 1.51 .. lokkkng nice I’m holding $YHC Bulls are in control holding for AH runner
0 · Reply
AltradoLinguini
AltradoLinguini Jul. 30 at 7:01 PM
$SLXN Here she goes! 🟩🟩🟩💰💰💰
0 · Reply
AltradoLinguini
AltradoLinguini Jul. 30 at 5:07 PM
$SLXN Delicious chart & setup for a momentum play here :) 🟩🟩🟩💰💰💰
0 · Reply
Latest News on SLXN
Silexion Therapeutics downgraded at Maxim on delisting and dilution risk

2026-07-29T18:15:22.000Z - 5 days ago

Silexion Therapeutics downgraded at Maxim on delisting and dilution risk

Silexion Therapeutics downgraded to Hold from Buy at Maxim

2026-07-29T18:05:16.000Z - 5 days ago

Silexion Therapeutics downgraded to Hold from Buy at Maxim

Silexion Therapeutics initiates SIL204 trial

2026-07-29T11:46:29.000Z - 5 days ago

Silexion Therapeutics initiates SIL204 trial

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Jul 29, 2026, 7:00 AM EDT - 5 days ago

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Jun 23, 2026, 8:40 AM EDT - 5 weeks ago

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics to Attend BIO International Convention 2026

Jun 16, 2026, 4:30 PM EDT - 6 weeks ago

Silexion Therapeutics to Attend BIO International Convention 2026

Silexion Therapeutics files to sell 859,609 ordinary shares for holders

2026-06-12T20:10:49.000Z - 7 weeks ago

Silexion Therapeutics files to sell 859,609 ordinary shares for holders

Silexion Therapeutics Corp trading halted, news pending

2026-05-28T23:50:59.000Z - 2 months ago

Silexion Therapeutics Corp trading halted, news pending

Silexion Therapeutics announces 1-for-10 reverse share split

2026-05-26T14:30:18.000Z - 2 months ago

Silexion Therapeutics announces 1-for-10 reverse share split

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

May 26, 2026, 8:30 AM EDT - 2 months ago

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

3 Penny Stocks to Watch Now, 5/21/26

2026-05-21T19:20:55.000Z - 2 months ago

3 Penny Stocks to Watch Now, 5/21/26

HCWB MTVA

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026, 8:30 AM EDT - 2 months ago

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

May 15, 2026, 8:27 AM EDT - 2 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

May 14, 2026, 9:27 AM EDT - 2 months ago

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204

2026-05-13T16:35:51.000Z - 2 months ago

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

May 13, 2026, 8:00 AM EDT - 2 months ago

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics submits SIL204 clinical trial application to Germany

2026-04-28T14:13:48.000Z - 3 months ago

Silexion Therapeutics submits SIL204 clinical trial application to Germany

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Apr 28, 2026, 8:45 AM EDT - 3 months ago

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

2026-03-24T13:50:15.000Z - 4 months ago

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Mar 24, 2026, 9:46 AM EDT - 4 months ago

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 17, 2026, 5:01 PM EDT - 4 months ago

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics urges shareholders to vote ahead of EGM

2026-03-05T13:22:21.000Z - 5 months ago

Silexion Therapeutics urges shareholders to vote ahead of EGM

Silexion Therapeutics issues letter to shareholders

2026-01-06T12:40:28.000Z - 7 months ago

Silexion Therapeutics issues letter to shareholders

Silexion submits Phase 2/3 trial application to Israel for SIL204

2025-12-16T13:45:35.000Z - 8 months ago

Silexion submits Phase 2/3 trial application to Israel for SIL204

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Dec 16, 2025, 8:40 AM EST - 8 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics initiated with a Buy at Litchfield Hills

2025-12-15T13:00:43.000Z - 8 months ago

Silexion Therapeutics initiated with a Buy at Litchfield Hills

Silexion receives positive feedback from German Health Authority for SIL204

2025-12-02T13:10:13.000Z - 8 months ago

Silexion receives positive feedback from German Health Authority for SIL204

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Nov 26, 2025, 7:30 AM EST - 8 months ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Silexion Therapeutics completes toxicology studies for SIL204

2025-11-25T14:20:40.000Z - 8 months ago

Silexion Therapeutics completes toxicology studies for SIL204

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Nov 25, 2025, 9:15 AM EST - 8 months ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year

2025-11-12T14:06:19.000Z - 9 months ago

Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 9 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics files to sell 1.29M ordinary shares for holders

2025-10-31T21:10:10.000Z - 9 months ago

Silexion Therapeutics files to sell 1.29M ordinary shares for holders

Silexion Therapeutics announces new data in SIL204

2025-09-30T12:50:48.000Z - 10 months ago

Silexion Therapeutics announces new data in SIL204

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 30, 2025, 8:40 AM EDT - 10 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Silexion Therapeutics files $100M mixed securities shelf

2025-09-26T20:35:21.000Z - 11 months ago

Silexion Therapeutics files $100M mixed securities shelf

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 25, 2025, 8:45 AM EDT - 11 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 9:17 AM EDT - 11 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 11, 2025, 7:00 AM EDT - 11 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 4, 2025, 9:25 AM EDT - 11 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:45 AM EDT - 11 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 8:00 PM EDT - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 31, 2025, 9:55 AM EDT - 1 year ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 16, 2025, 8:44 AM EDT - 1 year ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 1 year ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 1 year ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 1 year ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 1 year ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 1 year ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 1 year ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 1 year ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 2 years ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 2 years ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

gofefego
gofefego Aug. 3 at 8:34 PM
$SLXN https://chatgpt.com/s/t_6a70fb4479808191b26f557bdfaf3505
0 · Reply
gofefego
gofefego Aug. 3 at 8:20 PM
$SLXN has 1,06m outstanding shares with 806k float (Webull). Last week it announced it began phase 2/3 trial in pancreatic cancer. Today it announced it regained Nasdaq compliance. What else does it need to run like $DFNS $CYCU?
0 · Reply
Amuldee
Amuldee Aug. 3 at 4:03 PM
$SLXN come om
0 · Reply
focafoca99
focafoca99 Aug. 3 at 2:24 PM
$SLXN restores audit committee compliance with Nasdaq rule after board appointment.
0 · Reply
Amuldee
Amuldee Jul. 31 at 8:16 PM
$SLXN anyone here
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 31 at 6:07 PM
$SLXN overnight swing idea 1.51 and 1.60 so far $2+ now
1 · Reply
SFG1
SFG1 Jul. 30 at 7:40 PM
$SLXN Looks like somebody is "painting tape"
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 7:19 PM
$SLXN posted at bottomed 1..60 then again 1.51 .. lokkkng nice I’m holding $YHC Bulls are in control holding for AH runner
0 · Reply
AltradoLinguini
AltradoLinguini Jul. 30 at 7:01 PM
$SLXN Here she goes! 🟩🟩🟩💰💰💰
0 · Reply
AltradoLinguini
AltradoLinguini Jul. 30 at 5:07 PM
$SLXN Delicious chart & setup for a momentum play here :) 🟩🟩🟩💰💰💰
0 · Reply
SFG1
SFG1 Jul. 30 at 4:51 PM
$SLXN Straight back to the N.L.O.D
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 4:16 PM
$NUWE 225%+ today Next one to watch and could go at any moment $SLXN still buying zone here sub $2 level
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 3:57 PM
$SLXN put this bottomed oversold 1M floater on the radar buying opportunity while it’s here 1.50s/1.60s > 100%-500% range potential upside runner $YHC $DFNS $NUWE $CYCU
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 3:51 PM
$SLXN this is next exact set up and chart float like $NUWE ran $6+ or 225% so far from 1s Would load up $SLXN while its at low right now bottomed chart 1.50s > target 100%+ run 🏃‍♂️
1 · Reply
SFG1
SFG1 Jul. 30 at 2:19 PM
$SLXN The only thing this has going for it right now is the fact that it's trading at the All Time Low post recent RS and also the fact that the RSI is in oversold territory.... Other than those observations...The Trend ain't your friend
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 1:42 PM
$NUWE sub 2 buying opportunity now $6+ 225% love so far $SLXN next one same chart both low floaters .. sub 2 buying opportunity here 1.60 … $5+ run next
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 12:34 PM
$NUWE 200% $5+ NOW from sub 2 $SLXN next one to go > same chart like NUWE $DFNS still strong 💪🏾 $STKH $DCX
0 · Reply
Rasto2020
Rasto2020 Jul. 30 at 11:55 AM
$SLXN wow, this could get some bounce
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 30 at 10:16 AM
$NUWE 125% $4+ so far from sub 2 level .. still strong here pre market $SLXN watch this one break 2.40 > could rally .. sub 2 buying opportunity
1 · Reply
Amuldee
Amuldee Jul. 30 at 1:11 AM
$SLXN warrants are at 5 correct y the hech this dumped? ATM any guess
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 29 at 11:31 PM
$SLXN watch this one closely tomorrow
0 · Reply